Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 182
Filter
1.
Brasília; s.n; 1 ago. 2020.
Non-conventional in Portuguese | LILACS, BRISA, PIE | ID: biblio-1117735

ABSTRACT

O Informe Diário de Evidências é uma produção do Ministério da Saúde que tem como objetivo acompanhar diariamente as publicações científicas sobre tratamento farmacológico e vacinas para a COVID-19. Dessa forma, são realizadas buscas estruturadas em bases de dados biomédicas, referentes ao dia anterior desse informe. Não são incluídos estudos pré-clínicos (in vitro, in vivo, in silico). A frequência dos estudos é demonstrada de acordo com a sua classificação metodológica (revisões sistemáticas, ensaios clínicos randomizados, coortes, entre outros). Para cada estudo é apresentado um resumo com avaliação da qualidade metodológica. Essa avaliação tem por finalidade identificar o grau de certeza/confiança ou o risco de viés de cada estudo. Para tal, são utilizadas ferramentas já validadas e consagradas na literatura científica, na área de saúde baseada em evidências. Cabe ressaltar que o documento tem caráter informativo e não representa uma recomendação oficial do Ministério da Saúde sobre a temática. Foram encontrados 16 artigos.


Subject(s)
Pneumonia, Viral/drug therapy , Coronavirus Infections/drug therapy , Betacoronavirus/drug effects , Ascorbic Acid/therapeutic use , Technology Assessment, Biomedical , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , BCG Vaccine/therapeutic use , Colchicine/therapeutic use , Cross-Sectional Studies , Cohort Studies , Interferon-gamma/therapeutic use , Adrenal Cortex Hormones/therapeutic use , Antirheumatic Agents/therapeutic use , Ritonavir/therapeutic use , Interleukin 1 Receptor Antagonist Protein/therapeutic use , Lopinavir/therapeutic use , Interferon alpha-2/therapeutic use , Glucocorticoids/therapeutic use , Hydroxychloroquine/therapeutic use
2.
Brasília; s.n; 28 jul. 2020.
Non-conventional in Portuguese | LILACS, BRISA, PIE | ID: biblio-1117726

ABSTRACT

O Informe Diário de Evidências é uma produção do Ministério da Saúde que tem como objetivo acompanhar diariamente as publicações científicas sobre tratamento farmacológico e vacinas para a COVID-19. Dessa forma, são realizadas buscas estruturadas em bases de dados biomédicas, referentes ao dia anterior desse informe. Não são incluídos estudos pré-clínicos (in vitro, in vivo, in silico). A frequência dos estudos é demonstrada de acordo com a sua classificação metodológica (revisões sistemáticas, ensaios clínicos randomizados, coortes, entre outros). Para cada estudo é apresentado um resumo com avaliação da qualidade metodológica. Essa avaliação tem por finalidade identificar o grau de certeza/confiança ou o risco de viés de cada estudo. Para tal, são utilizadas ferramentas já validadas e consagradas na literatura científica, na área de saúde baseada em evidências. Cabe ressaltar que o documento tem caráter informativo e não representa uma recomendação oficial do Ministério da Saúde sobre a temática. Foram encontrados 18 artigos e 3 protocolos.


Subject(s)
Humans , Pneumonia, Viral/drug therapy , Coronavirus Infections/drug therapy , Betacoronavirus/drug effects , Acetylcysteine/therapeutic use , Ascorbic Acid/therapeutic use , Ribavirin/therapeutic use , Technology Assessment, Biomedical , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , BCG Vaccine/therapeutic use , Colchicine/therapeutic use , Cohort Studies , Adrenal Cortex Hormones/therapeutic use , Rho(D) Immune Globulin/therapeutic use , Azithromycin/therapeutic use , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Infliximab/therapeutic use , Alemtuzumab/therapeutic use , Interferon alpha-2/therapeutic use , Hydroxychloroquine/therapeutic use
4.
Medwave ; 20(6): e7978, 31-07-2020.
Article in English | LILACS | ID: biblio-1119706

ABSTRACT

OBJECTIVE: This living systematic review aims to provide a timely, rigorous, and continuously updated summary of the available evidence on the role of vitamin C in treating patients with COVID-19. DATA SOURCES: We conducted searches in PubMed/MEDLINE, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), grey literature, and in a centralized repository in L·OVE (Living OVerview of Evidence). In response to the COVID-19 emergency, L·OVE was adapted to expand the range of evidence it comprises and has been customized to group all COVID-19 evidence in one place. All the searches covered the period until April 29, 2020 (one day before submission). STUDY SELECTION AND METHODS: We adapted an already published standard protocol for multiple parallel systematic reviews. We searched for randomized trials evaluating the effect, in patients with COVID-19, of vitamin C versus placebo or no treatment. Anticipating the lack of randomized trials directly addressing this question, we also searched for trials evaluating MERS-CoV and SARS-CoV, and non-randomized studies in COVID-19. Two reviewers independently screened each study for eligibility. A living, web-based version of this review will be openly available during the COVID-19 pandemic, and we will resubmit it to the journal whenever there are substantial updates. RESULTS: We screened 95 records, but no study was considered eligible. We identified 20 ongoing studies, including 13 randomized trials evaluating vitamin C in COVID-19. CONCLUSIONS: We did not find any studies that met our inclusion criteria, and hence there is no evidence to support or refute the use of vitamin C in the treatment of patients with COVID-19. A substantial number of ongoing studies should provide valuable evidence to inform researchers and decision-makers soon.


OBJETIVO: Esta revisión sistemática viva tiene como objetivo proporcionar un resumen oportuno, riguroso y continuamente actualizado de la evidencia disponible sobre el papel de la vitamina C en el tratamiento de pacientes con COVID-19. FUENTES DE DATOS: Realizamos búsquedas en PubMed/MEDLINE, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), literatura gris y en un repositorio centralizado en L·OVE (Living OVerview of Evidence). En respuesta a la emergencia de COVID-19, L·OVE se adaptó para ampliar el rango de evidencia que cubre y se personalizó para agrupar toda la evidencia de COVID-19 en un solo lugar. Todas las búsquedas abarcaron el período hasta el 29 de abril de 2020 (un día antes de su envío). SELECCIÓN DE ESTUDIOS Y MÉTODOS: Adaptamos un protocolo común publicado para múltiples revisiones sistemáticas paralelas. Se buscaron ensayos aleatorios que evaluaran el efecto de la vitamina C versus placebo o ningún tratamiento en pacientes con COVID-19. Anticipando la falta de ensayos aleatorios que aborden directamente esta cuestión, también buscamos ensayos que evaluaran MERS-CoV y SARS-CoV, y estudios no aleatorios en COVID-19. Dos revisores seleccionaron de forma independiente cada estudio para determinar su elegibilidad. Una versión viva y basada en la web de esta revisión estará abiertamente disponible durante la pandemia de COVID-19, y se volverá a enviar a publicación cuando haya actualizaciones sustanciales. RESULTADOS: Se examinaron 95 registros, pero ningún estudio se consideró elegible. Se identificaron 20 estudios en curso, incluidos 13 ensayos aleatorios que evalúan la vitamina C en COVID-19. CONCLUSIONES: No se encontró ningún estudio que cumpliera con los criterios de inclusión, por lo que no hay evidencia para apoyar o refutar el uso de vitamina C en el tratamiento de pacientes con COVID-19. Un número sustancial de estudios en curso debería proporcionar evidencia valiosa para informar a los investigadores y los tomadores de decisiones en un futuro próximo.


Subject(s)
Humans , Ascorbic Acid/therapeutic use , Vitamins/therapeutic use , SARS-CoV-2 , COVID-19/therapy , Severe Acute Respiratory Syndrome/therapy , Pandemics
6.
Brasília; s.n; 5 jun. 2020.
Non-conventional in Portuguese | LILACS, BRISA, PIE | ID: biblio-1100288

ABSTRACT

O Informe Diário de Evidências é uma produção do Ministério da Saúde que tem como objetivo acompanhar diariamente as publicações científicas sobre tratamento farmacológico e vacinas para a COVID-19. Dessa forma, são realizadas buscas estruturadas em bases de dados biomédicas, referente ao dia anterior desse informe. Não são incluídos estudos pré-clínicos (in vitro, in vivo, in silico). A frequência dos estudos é demonstrada de acordo com a sua classificação metodológica (revisões sistemáticas, ensaios clínicos randomizados, coortes, entre outros). Para cada estudo é apresentado um resumo com avaliação da qualidade metodológica. Essa avaliação tem por finalidade identificar o grau de certeza/confiança ou o risco de viés de cada estudo. Para tal, são utilizadas ferramentas já validadas e consagradas na literatura científica, na área de saúde baseada em evidências. Cabe ressaltar que o documento tem caráter informativo e não representa uma recomendação oficial do Ministério da Saúde sobre a temática. Foram encontrados 11 artigos e 7 protocolos.


Subject(s)
Humans , Pneumonia, Viral/drug therapy , Coronavirus Infections/drug therapy , Betacoronavirus/drug effects , Ascorbic Acid/therapeutic use , Ribavirin/therapeutic use , Technology Assessment, Biomedical , Thalidomide/therapeutic use , Ceftriaxone/therapeutic use , Methylprednisolone/therapeutic use , Chloroquine/therapeutic use , Interferons/therapeutic use , Enoxaparin/therapeutic use , Azithromycin/therapeutic use , Ritonavir/therapeutic use , Angiotensin II Type 1 Receptor Blockers/therapeutic use , Lopinavir/therapeutic use , Vasopeptidase Inhibitors/therapeutic use , Hydroxychloroquine/therapeutic use
7.
Brasília; s.n; 11 maio 2020.
Non-conventional in Portuguese | LILACS, BRISA, PIE | ID: biblio-1097395

ABSTRACT

Essa é uma produção do Departamento de Ciência e Tecnologia (Decit) da Secretaria de Ciência, Tecnologia, Inovação e Insumos Estratégicos em Saúde (SCTIE) do Ministério da Saúde (Decit/SCTIE/MS), que tem como missão promover a ciência e tecnologia e o uso de evidências científicas para a tomada de decisão do SUS, tendo como principal atribuição o incentivo ao desenvolvimento de pesquisas em saúde no Brasil, de modo a direcionar os investimentos realizados em pesquisa pelo Governo Federal às necessidades de saúde pública. Informar sobre as principais evidências científicas descritas na literatura internacional sobre tratamento farmacológico para a COVID-19. Além de resumir cada estudo identificado, o informe apresenta também uma avaliação da qualidade metodológica e a quantidade de artigos publicados, de acordo com a sua classificação metodológica (revisões sistemáticas, ensaios clínicos randomizados, entre outros). Foram encontrados 16 artigos e 17 protocolos.


Subject(s)
Humans , Pneumonia, Viral/drug therapy , Coronavirus Infections/drug therapy , Disease Progression , Betacoronavirus/drug effects , Ascorbic Acid/therapeutic use , Ribavirin/therapeutic use , Methylprednisolone/therapeutic use , Chloroquine/therapeutic use , Adrenal Cortex Hormones/therapeutic use , Azithromycin/therapeutic use , Ritonavir/therapeutic use , Drug Combinations , Interleukin 1 Receptor Antagonist Protein/therapeutic use , Lopinavir/therapeutic use , Interferon beta-1b/therapeutic use , Glucocorticoids/therapeutic use , Hydroxychloroquine/therapeutic use
8.
Prensa méd. argent ; 106(1): 1-5, 20200000. fig
Article in Spanish | LILACS, BINACIS | ID: biblio-1369670

ABSTRACT

El escorbuto es una enfermedad ocasionada por el déficit de vitamina C. La vitamina C, también llamada ácido ascórbico, actúa como cofactor de la propil-lisil hidroxilasa, enzima que interviene en la biosíntesis de colágeno; por ello es de vital importancia en la integridad estructural de piel, mucosas, anexos, vasos sanguíneos, huesos y dientes. Las manifestaciones clínicas incluyen síntomas constitucionales severos como debilidad y fatiga. Los hallazgos cutáneos iniciales son pápulas hiperqueratósicas foliculares y púrpura palpable perifolicular. Con el tiempo aparecen áreas extensas de equimosis, edema en miembros inferiores, hemorragias en astillas en uñas y alopecia difusa. Por lo general se describe esta enfermedad como asociada a tiempos pasados y extremadamente infrecuente en países desarrollados. Sin embargo, actualmente se ha detectado un aumento en el número de casos, asociados con malnutrición severa. Desórdenes psiquiátricos como la anorexia nerviosa, alcoholismo y deficiencias nutricionales por dietas excesivas y mal balanceadas o escasez de recursos económicos constituyen los principales factores de riesgo hoy en día. El tratamiento consiste en la corrección del déficit mediante la mediante suplementación con vitamina C vía oral. Presentamos una mujer de 24 años con escorbuto asociado a anorexia nerviosa y a dieta pobre en vegetales y fruta.


Scurvy is a disease caused by a deficit of vitamin C. Vitamin C, also called ascorbic acid, acts as a cofactor for propyl-lysyl hydroxylase, an enzyme that is involved in collagen biosynthesis, vitally important in the structural integrity of skin, mucous membranes, annexes, blood vessels, bones and teeth. Clinical manifestations include severe constitutional symptoms such as weakness and fatigue. The initial cutaneous findings are follicular hyperkeratotic papules and perifollicular palpable purpura. Over time, large areas of ecchymosis, edema of the lower limbs, splinter hemorrhages in nails and diffuse alopecia appear. Usually this disease is described as associated with past times and extremely uncommon in developed countries. However, the number of cases have been increasing, especially those associated with severe malnutrition. Psychiatric disorders such as anorexia nervosa, alcoholism and nutritional deficiencies due to excessive and poorly balanced diets or shortage of economic resources are the main risk factors nowadays. Correcting the deficit with oral vitamin C supplementation is the treatment of the disease. We present a 24-year-old woman with scurvy associated with anorexia nervosa and a diet low in vegetables and fruit.


Subject(s)
Humans , Female , Adult , Purpura , Ascorbic Acid/therapeutic use , Ascorbic Acid Deficiency/therapy , Scurvy/diagnosis , Deficiency Diseases/therapy , Malnutrition/complications , Early Diagnosis
9.
Dermatol. argent ; 26(1): 38-41, 2020. ilus
Article in Spanish | LILACS | ID: biblio-1146325

ABSTRACT

El escorbuto es una enfermedad causada por la deficiencia de vitamina C o ácido ascórbico. Sus manifestaciones clínicas son variadas debido a que esa vitamina es un cofactor de enzimas que intervienen en numerosos procesos, como la síntesis de colágeno y la absorción de diferentes nutrientes. La expresión cutánea característica son las petequias foliculares con pelos en cuello de cisne y en tirabuzón. El compromiso mucoso se manifiesta como hipertrofia y hemorragia gingival, gingivitis y pérdida de piezas dentarias. El diagnóstico es clínico y puede confirmarse mediante la determinación de la vitamina C plasmática o leucocitaria. El tratamiento se basa en el aporte suplementario de esa vitamina. Se presenta el caso de un paciente de 32 años con escorbuto debido a una dieta casi exclusivamente a base de harinas y carente de frutas y verduras. (AU)


Scurvy is a disease caused by vitamin C deficiency (also called ascorbic acid). Its clinical manifestations are varied because this vitamin is a cofactor of enzymes that take part in numerous processes, such as the synthesis of collagen and the absorption of different nutrients. Cutaneous expression of scurvy is follicular petechiae with corkscrew hairs. Mucous involvement manifests as gingival hypertrophy and bleeding, gingivitis and loss of teeth. The diagnosis of this entity is clinical and can be confirmed by plasma or leukocyte vitamin C dosing. The treatment consists of vitamin C supplementation. We present a 32-year-old male patient with scurvy secondary to a diet based almost exclusively on flour and lacking in fruits and vegetables. (AU)


Subject(s)
Humans , Male , Adult , Young Adult , Scurvy/diagnosis , Ascorbic Acid/therapeutic use , Scurvy/therapy , Vitamins/therapeutic use
11.
Rev. bras. cir. cardiovasc ; 33(2): 129-134, Mar.-Apr. 2018. tab, graf
Article in English | LILACS | ID: biblio-958390

ABSTRACT

Abstract Objective: The aim of this study was to investigate the impact of perioperative administration of N-acetylcysteine, selenium and vitamin C on the incidence and outcomes of acute kidney injury after off-pump coronary bypass graft surgery. Methods: 291 patients requiring elective off-pump coronary bypass graft surgery were randomized to receive either N-acetylcysteine, vitamin C and selenium 600 mg, 1500 mg, 0.5 mg, and nothing orally twice a day, respectively, from the day before to 2 days after surgery. They were assessed for the development of acute kidney injury using Acute Kidney Injury Network criteria, time of onset, its severity and duration, duration of mechanical ventilation, intensive care unit and hospital length of stay, and in-hospital mortality. Results: 272 patients completed the study. The total incidence of acute kidney injury was 22.1% (n=60) with 14 (20.9%), 15 (22.1%), 21 (31.8%), and 10 (14.1%) patients in the vitamin C, NAC, selenium, and control groups, respectively (P=0.096). We did not register significant differences in the incidence, the time of occurrence, the severity and the duration of acute kidney injury, as well as the duration of mechanical ventilation, the intensive care unit and hospital length of stay, and the in-hospital mortality among the four groups. Conclusion: We found that perioperative administration of N-acetylcysteine, vitamin C and selenium were not effective in preventing acute kidney injury and associated morbidity and mortality after off-pump coronary bypass graft surgery.


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Aged, 80 and over , Acetylcysteine/therapeutic use , Ascorbic Acid/therapeutic use , Selenium/therapeutic use , Coronary Artery Bypass, Off-Pump/adverse effects , Acute Kidney Injury/etiology , Acute Kidney Injury/prevention & control , Antioxidants/therapeutic use , Respiration, Artificial , Severity of Illness Index , Treatment Outcome , Hospital Mortality , Renal Replacement Therapy , Risk Assessment , Creatinine/blood , Coronary Artery Bypass, Off-Pump/mortality , Acute Kidney Injury/mortality , Glomerular Filtration Rate , Length of Stay
12.
Medwave ; 18(6): e7260, 2018.
Article in English, Spanish | LILACS | ID: biblio-948468

ABSTRACT

Resumen INTRODUCCIÓN: El resfrío común causa una gran morbilidad en todo el mundo y no se cuenta con agentes terapéuticos eficaces contra éste. Existe la creencia de que ingerir vitamina C durante un episodio de resfrío ayuda a disminuir la duración y severidad de los síntomas, sin embargo existe controversia respecto a esta afirmación. MÉTODOS: Para responder esta pregunta utilizamos Epistemonikos, la mayor base de datos de revisiones sistemáticas en salud, la cual es mantenida mediante búsquedas en múltiples fuentes de información, incluyendo MEDLINE, EMBASE, Cochrane, entre otras. Extrajimos los datos desde las revisiones identificadas, reanalizamos los datos de los estudios primarios, realizamos un metanálisis y preparamos una tabla de resumen de los resultados utilizando el método GRADE. RESULTADOS Y CONCLUSIONES: Identificamos cuatro revisiones sistemáticas que en conjunto incluyeron ocho estudios primarios, de los cuales siete son ensayos aleatorizados. Concluimos que la vitamina C tiene un impacto mínimo o nulo en la duración del resfrío y en los días en casa o sin trabajar.


Abstract INTRODUCTION: The common cold causes great morbidity throughout the world and there are no effective therapeutic agents against it. There is a belief that consuming vitamin C during a cold episode would help reduce duration and severity of symptoms. However, there is controversy about this claim. METHODS: To answer this question we used Epistemonikos, the largest database of systematic reviews in health, which is maintained by screening multiple information sources, including MEDLINE, EMBASE, Cochrane, among others. We extracted data from the systematic reviews, reanalyzed data of primary studies, conducted a meta-analysis and generated a summary of findings table using the GRADE approach. RESULTS AND CONCLUSIONS: We identified four systematic reviews that included eight primary studies overall, of which seven were randomized trials. We concluded vitamin C has minimal or no impact on the duration of common cold or in the number of days at home or out of work.


Subject(s)
Humans , Ascorbic Acid/therapeutic use , Common Cold/drug therapy , Time Factors , Severity of Illness Index , Randomized Controlled Trials as Topic , Databases, Factual , Treatment Outcome
13.
Braz. j. med. biol. res ; 51(4): e7097, 2018. graf
Article in English | LILACS | ID: biblio-889063

ABSTRACT

Vitamin E (vit. E) and vitamin C (vit. C) are antioxidants that inhibit nociception. The effect of these vitamins on oxidative-stress markers in the spinal cord of rats with chronic constriction injury (CCI) of the sciatic nerve is unknown. This study investigated the effect of intraperitoneal administration of vit. E (15 mg·kg-1·day-1) and vit. C (30 mg·kg-1·day-1), given alone or in combination, on spinal cord oxidative-stress markers in CCI rats. Adult male Wistar rats weighing 200-250 g were divided equally into the following groups: Naive (rats did not undergo surgical manipulation); Sham (rats in which all surgical procedures involved in CCI were used except the ligature), and CCI (rats in which four ligatures were tied loosely around the right common sciatic nerve), which received injections of vitamins or vehicle (saline containing 1% Tween 80) for 3 or 10 days (n=6/each group). The vitamins prevented the reduction in total thiol content and the increase in superoxide-anion generation that were found in vehicle-treated CCI rats. While nitric-oxide metabolites increased in vehicle-treated CCI rats 3 days after surgery, these metabolites did not show significant changes in vitamin-treated CCI rats. In all rats, total antioxidant capacity and hydrogen-peroxide levels did not change significantly. Lipid hydroperoxides increased 25% only in vehicle-treated CCI rats. These changes may contribute to vit. C- and vit. E-induced antinociception, because scavenging reactive oxygen species seems to help normalize the spinal cord oxidative status altered by pain.


Subject(s)
Animals , Male , Rats , alpha-Tocopherol/therapeutic use , Antioxidants/therapeutic use , Ascorbic Acid/therapeutic use , Oxidative Stress/drug effects , Sciatic Neuropathy/drug therapy , Spinal Cord/drug effects , Biomarkers/metabolism , Disease Models, Animal , Pain Measurement , Pain Threshold/drug effects , Rats, Wistar , Sciatic Neuropathy/metabolism , Spinal Cord/metabolism
14.
Rev. bras. cir. cardiovasc ; 32(3): 197-201, May-June 2017. tab, graf
Article in English | LILACS | ID: biblio-897909

ABSTRACT

Abstract Objective: Ischemia-reperfusion injury after acute ischemia treatment is a serious condition with high mortality and morbidity. Ischemia-reperfusion injury may result in organ failure particularly in kidney, lung, liver, and heart. In our study, we investigated the effects of papaverine and vitamin C on ischemia-reperfusion injury developed in the rat liver after occlusion-reperfusion of rat aorta. Methods: 32 Sprague-Dawley female rats were randomized into four groups (n=8). Ischemia was induced with infrarenal aortic cross-clamping for 60 minutes; then the clamp was removed and reperfusion was allowed for 120 minutes. While the control group and the ischemia-reperfusion group did not receive any supplementary agent, two other groups received vitamin C and papaverine hydrochloride (papaverine HCL). Liver tissues were evaluated under the light microscope. Histopathological examination was assessed by Suzuki's criteria and results were compared between groups. Results: In ischemia-reperfusion group, severe congestion, severe cytoplasmic vacuolization, and parenchymal necrosis over 60% (score 4) were observed. In vitamin C group, mild congestion, mild cytoplasmic vacuolization and parenchymal necrosis below 30% (score 2) were found. In papaverine group, moderate congestion, moderate cytoplasmic vacuolization and parenchymal necrosis below 60% (score 3) were observed. Conclusion: An ischemia of 60 minutes induced on lower extremities causes damaging effects on hepatic tissue. Vitamin C and papaverine are helpful in reducing liver injury after acute ischemia reperfusion and may partially avoid related negative conditions.


Subject(s)
Animals , Female , Papaverine/pharmacology , Ascorbic Acid/pharmacology , Vasodilator Agents/pharmacology , Reperfusion Injury/prevention & control , Liver/drug effects , Liver/blood supply , Antioxidants/pharmacology , Aorta, Abdominal , Papaverine/therapeutic use , Ascorbic Acid/therapeutic use , Time Factors , Reperfusion Injury/pathology , Random Allocation , Rats, Sprague-Dawley , Constriction , Disease Models, Animal , Liver/pathology , Necrosis , Antioxidants/therapeutic use
15.
Rev. Soc. Bras. Med. Trop ; 50(2): 184-193, Mar.-Apr. 2017. tab, graf
Article in English | LILACS | ID: biblio-842842

ABSTRACT

Abstract INTRODUCTION: Stimulation of inflammatory mediators such as cytokines and chemokines may cause oxidative stress in Chagas disease. In this study, we evaluated the merit of vitamins C and E as antioxidant therapy to minimize the oxidative stress-induced damage in an experimental model of Chagas disease. METHODS: Ninety-six Swiss mice were infected with Trypanosoma cruzi QM2 and treated with vitamins C, E, or both (C/E) for 60 and 120 days, and their effects compared to placebo administration were evaluated in the acute and chronic disease phases. RESULTS: There was no difference in parasitemia among treatment groups. However, histological analysis showed more severe inflammation in the skeletal muscle in the vitamin supplementation groups at both the acute and chronic phases. Biochemical analyses during the acute phase showed increased ferric-reducing ability of plasma (FRAP) and glutathione (GSH) levels in the vitamin C and C/E groups. In the chronic phase, a decrease in GSH levels was observed in the vitamin E group and a decrease in thiobarbituric acid reactive substances (TBARS) was observed in the vitamin C/E group. Moreover, there was a decrease in TBARS in the cardiac tissues of the vitamin C and C/E groups compared to that of the placebo group, although this level was greater in the vitamin E group than in the vitamin C group. CONCLUSIONS: The antioxidant action of vitamins C and E reduced oxidative stress in both the acute and chronic phases of Chagas disease, with a marked effect from joint administration, indicating their inherent synergism.


Subject(s)
Animals , Male , Ascorbic Acid/therapeutic use , Vitamin E/therapeutic use , Chagas Disease/therapy , Oxidative Stress/drug effects , Antioxidants/therapeutic use , Acute Disease , Chronic Disease , Chagas Disease/metabolism , Parasitemia/drug therapy , Disease Models, Animal , Mice
16.
Rev. cuba. plantas med ; 21(4)oct.-dic. 2016. ilus, graf, tab
Article in Spanish | LILACS, CUMED | ID: biblio-960661

ABSTRACT

Introducción: la Annona muricata L. (guanábana) es una de las frutas con mayor contenido vitamínico, además posee minerales como sodio, calcio, magnesio, potasio, fósforo y hierro. En Colombia se comercializa en fresco constituyéndose en toda una industria que representa ganancia para los fruticultores, al ser considerada como una de las frutas tropicales más gustosas y promisorias. Objetivo: caracterizar la pulpa de A. muricata cultivada en norte del departamento de Bolívar-Colombia. Métodos: A. muricata fue recolectada en el municipio de Turbana, ubicado en el norte del departamento de Bolívar (10º 16' 22″ latitud norte y 75º 26' 38″ longitud oeste). La pulpa de la guanábana se obtuvo a partir del fruto; y le se determinó pH, Brix, acidez titulable, índice de madurez, contenido de vitamina C (ácido ascórbico), humedad, ceniza, grasa, proteínas, fibra cruda, carbohidratos y minerales (Ca2+, Mg2+, Na+ , Fe2+ y K+). Resultados: el rendimiento de la pulpa fue del 75 por ciento, los sólidos solubles totales 14,10°Brix, acidez 0,87 por ciento ácido málico, índice de maduración 16,21, pH 3,97, ceniza 0,70 por ciento, humedad 81,49 por ciento, proteína 1,49por ciento, grasa 0,2 por ciento, fibra cruda 1,64 por ciento, carbohidratos 16,12 por ciento y Vitamina C 27,44 mg ácido ascórbico. El mineral más abundante presente en la pulpa de la guanábana es el potasio con un valor de 45,2 mg. Conclusiones: la pulpa de A. muricata es considerado como promisorio para diseñar productos nutracéuticos por su elevado contenido de vitamina C(AU)


Introduction: Annona muricata L. (soursop) is one of the fruits with the highest content of vitamins, as well as minerals like sodium, calcium, magnesium, potassium, phosphorus and iron. In Colombia it is sold fresh, and constitutes a whole industry yielding profits for its growers, being as it is one of the tastiest and promising fruits. Objective: Characterize the pulp of A. muricata grown in the north of Bolívar Department in Colombia. Methods: A. muricata was collected from the municipality of Turbana, in the north of Bolívar Department (10º16?22?N 75º26?38?W). The soursop pulp was obtained from the fruit. Determination was made of pH, Brix, titratable acidity, maturation index, content of vitamin C (ascorbic acid), humidity, ash, fat, proteins, crude fiber, carbohydrates and minerals (Ca2+, Mg2+, Na+, Fe2+ and K+). Results: The following results were obtained: pulp yield 75 percent, total soluble solids 14, 10°Brix, acidity 0.87 percent malic acid, maturation index 16.21, pH 3.97, ash 0.70 percent, humidity 81.49 percent, protein 1.49 percent fat 0.2 percent, crude fiber 1.64 percent, carbohydrates 16.12 percent and vitamin C 27.44 mg ascorbic acid. The most abundant mineral in soursop pulp was potassium, with 45.2 mg. Conclusions: A. muricata pulp is considered to be promising for the design of nutraceutical products, due to its high vitamin C content(AU)


Subject(s)
Humans , Ascorbic Acid/therapeutic use , Annona , Colombia
17.
Rev. Assoc. Med. Bras. (1992) ; 62(7): 680-686, Oct. 2016. tab, graf
Article in English | LILACS | ID: biblio-829514

ABSTRACT

Summary This review is aimed at the systematic mapping of ascorbic acid in the prevention and/or treatment of cancer in clinical and non-clinical studies from 2011 to 2015, in order to understand dose-response variations as well as its mechanisms of action as an antioxidant and antitumor agent. Seventy-eight articles were retrieved from the PubMed/Bireme database, of which only 30 included ascorbic acid in the prevention and/or treatment of cancer. However, there are controversies regarding doses and a lack of clinical studies featuring its mechanism of action more clearly. Other studies are needed to understand dose-response variations, as well as its targeting mechanisms of action, both as an antioxidant and antitumor agent, to assist treatment and prevention of cancer, aiming at better quality of life for both patients and the general population.


Resumo Este estudo de revisão teve como objetivo fazer o mapeamento sistemático do ácido ascórbico na prevenção e/ou no tratamento do câncer como antioxidante e/ou pró-oxidante em estudos clínicos e não clínicos, entre 2011 e 2015, para o entendimento das variações de dose-resposta, bem como dos seus mecanismos de ação como agente antioxidante e antitumoral. Nas bases de dados Pubmed e Bireme, foram identificados 78 artigos, dos quais apenas 30 apontavam o ácido ascórbico na prevenção e/ou no tratamento do câncer. Contudo, há controvérsias sobre as doses utilizadas e faltam estudos clínicos que caracterizem melhor o seu mecanismo de ação. Outros estudos devem ser realizados para o entendimento das variações de dose-resposta, bem como de seus mecanismos de ação, como agente antioxidante ou antitumoral, para auxiliar o tratamento e a prevenção do câncer, visando à melhor qualidade de vida dos pacientes e da população em geral.


Subject(s)
Humans , Ascorbic Acid/therapeutic use , Neoplasms/prevention & control , Neoplasms/drug therapy , Antineoplastic Agents/therapeutic use , Antioxidants/therapeutic use , Reproducibility of Results , Treatment Outcome , Apoptosis/drug effects , Dose-Response Relationship, Drug
18.
Arch. endocrinol. metab. (Online) ; 60(4): 328-332, Aug. 2016. tab, graf
Article in English | LILACS | ID: lil-792949

ABSTRACT

ABSTRACT Objective The objective of this study, in addition to confirming that therapy with 131I causes oxidative stress, was to evaluate the effect of supplementation with vitamins C and E and selenium on this phenomenon by measuring plasma 8-epi-PGF2a, a marker of lipid peroxidation. Subjects and methods Forty patients with thyroid cancer submitted to thyroidectomy, who received 3.7 GBq 131I after levothyroxine withdrawal, were selected; 20 patients did not receive (control group) and 20 patients received (intervention group) daily supplementation consisting of 2000 mg vitamin C, 1000 mg vitamin E and 400 µg selenium for 21 days before 131I. Plasma 8-epi-PGF2a was measured immediately before and 2 and 7 days after 131I. Results A significant increase in plasma 8-epi-PGF2a after 131I was observed in the two groups. The concentrations of 8-epi-PGF2α were significantly higher in the control group before and 2 and 7 days after 131I. The percentage of patients with elevated 8-epi-PGF2α was also significantly higher in the control group before and after 131I. Furthermore, the increase (percent) in 8-epi-PGF2α was significantly greater in the control group (average of 112.3% versus 56.3%). Only two patients (10%) reported side effects during supplementation. Conclusions Ablation with 131I causes oxidative stress which can be minimized by the use of antioxidants.


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Young Adult , Thyroid Neoplasms/radiotherapy , Carcinoma/radiotherapy , Dinoprost/analogs & derivatives , Oxidative Stress/radiation effects , Iodine Radioisotopes/adverse effects , Antioxidants/therapeutic use , Ascorbic Acid/therapeutic use , Time Factors , Carcinoma/surgery , Carcinoma/metabolism , Carcinoma/drug therapy , Dinoprost/blood , Lipid Peroxidation/radiation effects , Prospective Studies , Reproducibility of Results , Analysis of Variance , Treatment Outcome , Dietary Supplements
19.
Article in English | LILACS | ID: lil-785819

ABSTRACT

ABSTRACT INTRODUCTION: Several approaches have been tried for the treatment of tinnitus, from cognitive-behavioral therapies and sound enrichment to medication. In this context, antioxidants, widely used in numerous areas of medicine, appear to represent a promising approach for the control of this symptom, which often is poorly controlled. OBJECTIVE: To evaluate the effects of antioxidant therapy for tinnitus in a group of elderly patients. METHODS: Prospective, randomized, double-blinded, placebo-controlled clinical trial. The sample consisted of 58 subjects aged 60 years or older, with a complaint of tinnitus associated with sensorineural hearing loss. These individuals completed the Tinnitus Handicap Inventory (THI) questionnaire before and after six months of therapy. The treatment regimens were: Ginkgo biloba dry extract (120 mg/day), a-lipoic acid (60 mg/day) + vitamin C (600 mg/day), papaverine hydrochloride (100 mg/day) + vitamin E (400 mg/day), and placebo. RESULTS: There was no statistically significant difference between THI by degree (p = 0.441) and by score (p = 0.848) before and after treatment. CONCLUSION: There was no benefit from the use of antioxidant agents for tinnitus in this sample.


Resumo Introdução: Uma série de abordagens terapêuticas tem sido empregada no tratamento do zumbido, desde terapias cognitivo-comportamentais e de enriquecimento sonoro até terapias medicamentosas. Nesse contexto, os agentes antioxidantes, amplamente utilizados em diversas áreas da medicina, parecem representar uma perspectiva promissora para o controle desse sintoma, que muitas vezes tem um controle clínico insatisfatório. Objetivo: Avaliar os efeitos da terapia com agentes antioxidantes sobre o zumbido em um grupo de pacientes idosos. Método: Ensaio clínico prospectivo, randomizado, duplo-cego e controlado por placebo. A amostra composta de 58 indivíduos com 60 anos ou mais, com queixa clínica de zumbido associado à perda auditiva, do tipo neurossensorial, em graus variados. Esses indivíduos foram submetidos ao questionário THI (Tinnitus Handicap Inventory) antes e após 6 meses de uso da medicação. Os esquemas terapêuticos foram os seguintes: extrato seco de Ginkgo biloba(120 mg/dia), ácido a-lipóico (60 mg/dia) + vitamina C (600 mg/dia), cloridrato de papaverina(100 mg/dia) + vitamina E (400 mg/dia) e placebo. Resultados: O THI após o tratamento foi estatisticamente igual ao THI antes do tratamento, tanto em graus (p = 0,441) quanto em escores (p = 0,848). Conclusão: Não se verificou benefício estatisticamente significativo com o uso de agentes antioxidantes para o zumbido dos indivíduos avaliados.


Subject(s)
Humans , Male , Female , Middle Aged , Aged , Aged, 80 and over , Tinnitus/drug therapy , Plant Extracts/therapeutic use , Ginkgo biloba/chemistry , Hearing Loss, Sensorineural/complications , Antioxidants/therapeutic use , Papaverine/therapeutic use , Ascorbic Acid/therapeutic use , Socioeconomic Factors , Tinnitus/complications , Vitamin E/therapeutic use , Severity of Illness Index , Double-Blind Method , Prospective Studies , Thioctic Acid/therapeutic use , Treatment Outcome , Phytotherapy/methods
20.
Int. j. morphol ; 33(1): 137-143, Mar. 2015. ilus
Article in Spanish | LILACS | ID: lil-743776

ABSTRACT

Debido al daño de la piel producto de quemaduras, los microorganismos encuentran condiciones favorables para su desarrollo, produciéndose desnaturalización, necrosis, exudado, congestión y edema. La miel posee actividad antioxidante, antiinflamatoria y antibacteriana. A su vez, el ácido ascórbico mejora la barrera epidérmica y reduce la contracción de heridas, entre otros. El objetivo de esta investigación fue evaluar morfológicamente la cicatrización de heridas con un tratamiento en base a miel de ulmo (Eucryphia cordifolia) suplementada con ácido ascórbico, comparando su efecto con miel de ulmo no suplementada, en heridas causadas por quemaduras de tipo B. La investigación fue aprobada por el Comité Ético Científico de la Universidad de La Frontera. Se trabajó con 15 cobayos (Cavia porcellus) distribuidos en tres grupos: MS (miel suplementada), M (miel), y Control+ (Hidrogel-Tull). Se provocó una quemadura en seco en el dorso del tórax de 1 cm de diámetro, que abarcó hasta el límite de la fascia profunda. Al día 10 de tratamiento, se extrajeron las biopsias y se depositaron en PBS. Posteriormente, fueron fijadas en formalina tamponada y procesadas para fines histológicos, realizándose las técnicas de VGE, VGC, PAS, y Sirius Red. El cobayo se utilizó como modelo animal por tener un metabolismo dependiente de ácido ascórbico. El grupo MS mostró un rápido debridamiento en comparación a los grupos control, con cierre epidermal en el 60% de las muestras, observándose una fase proliferativa avanzada. El grupo M no regeneró la capa epidérmica y presentó una fase proliferativa inicial. Los resultados de este estudio evidenciaron que al suplementar la miel de ulmo con ácido ascórbico se logra una cicatrización más rápida, con respecto a la miel de ulmo no suplementada, en heridas causadas por quemaduras.


Skin damage from burns creates favorable conditions for microorganism development, producing denaturation, necrosis, discharge, congestion and edema. Honey contains antioxidant, anti-inflammatory and antibacterial properties. At the same time ascorbic acid reduces the epidermal barrier and wound contraction, among others. The objective of this research was to morphologically evaluate wound healing with treatment based on Ulmo honey (E. cordifolia) supplemented with ascorbic acid, comparing its effect with unsupplemented Ulmo honey, in wounds caused by type B burns. The research was approved by the Scientific Ethics Committee of the Universidad de La Frontera. We worked with 15 guinea pigs (Cavia porcellus) divided into three groups: SH (supplemented honey), H (honey), and Control + (Hydrogel-Tulle). A 1 cm diameter dry burn was caused on the back of the chest and covered the extent of the deep fascia. At day 10 of treatment, biopsies were removed and placed in PBS. They were subsequently fixed in buffered formalin and processed for histological purposes, with VGE, VGC, PAS, and Sirius Red techniques. The guinea pig was used as an animal model for having a metabolism dependent on ascorbic acid. The SH group showed a rapid debridement compared to control groups, with epidermal closure in 60% of the samples, and advanced proliferative phase was observed. The H group did not regenerate epidermal layer and showed an initial proliferative phase. The results of this study showed that supplementing Ulmo honey with ascorbic acid achieves faster healing when compared to unsupplemented Ulmo honey in wounds caused by burns.


Subject(s)
Animals , Guinea Pigs , Ascorbic Acid/therapeutic use , Wound Healing/drug effects , Burns/drug therapy , Honey , Combined Modality Therapy
SELECTION OF CITATIONS
SEARCH DETAIL